Lexaria Bioscience Corp. (NASDAQ: LEXX) announced that the Material Transfer Agreement (MTA) originally entered into on August 30, 2024 with a pharmaceutical company ("PharmaCO") has been extended through December 31, 2026. The extension allows time for PharmaCO to receive and review Lexaria's 2026 research and development (R&D) results related to GLP-1 drugs. The MTA, which evaluates Lexaria's DehydraTECH technology in a pre-clinical setting, will continue to keep a temporary exclusive license active and in force. The parties will also engage in additional strategic planning discussions with PharmaCO's human clinical and business development teams.
The extension builds on progress from the past 12 months, during which Lexaria advanced its GLP-1 development program. The company recently announced progress in its 2026 R&D studies: Human Study #7, Animal Study #1, and Animal Study #2. All studies are within the GLP-1 sector and are designed to provide comprehensive evidence to facilitate further collaboration and potential licensing of Lexaria's technology. Each study is fully funded with existing corporate resources, with results expected during Q3 and Q4 of 2026.
DehydraTECH is Lexaria's patented drug delivery formulation and processing platform that improves oral delivery of drugs by increasing bio-absorption, reducing side effects, and enhancing blood-brain barrier penetration. The company operates a licensed in-house research laboratory and holds an intellectual property portfolio with 65 patents granted and additional patents pending worldwide. The extension of the MTA with PharmaCO underscores the potential of DehydraTECH in the growing GLP-1 drug market, which includes treatments for diabetes and obesity. Continued collaboration could lead to licensing deals that provide Lexaria with revenue and validate its technology.
The agreement's extension also highlights the importance of Lexaria's ongoing studies. Positive results from these studies could strengthen the company's position in negotiations with PharmaCO and other potential partners. The GLP-1 sector is highly competitive, and Lexaria's ability to secure and extend such agreements suggests its technology offers unique advantages. Investors and industry observers will closely watch the outcomes of the 2026 studies, as they could significantly impact Lexaria's valuation and strategic direction.
Lexaria cautions that forward-looking statements in this release involve risks and uncertainties, including market conditions, regulatory approvals, and scientific discovery. The company disclaims any obligation to update these statements except as required by law. For more information, visit Lexaria Bioscience's website.
